Scientific Project 2: HIV AIDS Defining molecular signatures in humans following vaccination that can inform pathways to protective immunity against HIV-1 infection

科学项目 2：HIV AIDS 定义人类接种疫苗后的分子特征，为针对 HIV-1 感染的保护性免疫途径提供信息

• 批准号: 10631105
• 负责人: Margaret Juliana McElrath
• 金额: $ 13.48万
• 依托单位: SEATTLE CHILDREN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-07-19 至 2027-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10631105
• 关键词: 2019-nCoV; AIDS prevention; Acceleration; Acquired Immunodeficiency Syndrome; Active Immunization; Adjuvant; Africa; Antibodies; Antibody-mediated protection; Antigenic Specificity; Antigens; Architecture; Area; B cell repertoire; B-Lymphocytes; Benchmarking; Biological Assay; Bone Marrow; CD4 Positive T Lymphocytes; CD8-Positive T-Lymphocytes; Cell physiology; Cells; Circulation; Data Sources; Development; Epidemic; Epitopes; Evaluation; Evolution; Formulation; Generations; Goals; HIV; HIV Infections; HIV Vaccine Trials Network; HIV vaccine; HIV-1; HIV/AIDS; Helper-Inducer T-Lymphocyte; Human; Immune; Immune response; Immunity; Immunization; Infection; Innate Immune Response; Investigation; Knowledge; Libraries; Malaria; Measures; Metadata; Molecular; Molecular Profiling; Participant; Pathway interactions; Peripheral; Phase; Phenotype; Placebos; Plasma Cells; Population; Population Heterogeneity; Prevention; Preventive; Proteomics; Protocols documentation; Regimen; SARS-CoV-2 infection; Safety; Serology; Source; System; T cell receptor repertoire sequencing; T cell response; T-Cell Immunologic Specificity; T-Cell Receptor; T-Lymphocyte; Technology; Testing; Tissues; Translating; Vaccination; Vaccine Design; Vaccines; Viral; adaptive immune response; analytical tool; draining lymph node; efficacy trial; in vivo; insight; lymph nodes; multimodality; neutralizing antibody; novel; polyclonal antibody; prevent; primary endpoint; response; study population; success; vaccine efficacy; vaccine trial

The overall goal of HIPC3 Project 2 is to identify human molecular signatures induced by HIV-1 vaccines and adjuvant formulations that are of potential relevance to protection against HIV-1 infection in diverse populations. Our proposed investigations will focus on three areas where critical insights are needed: 1) comprehensive assessment and comparison of the quality and enhanced potency and durability of immune responses following immunization with a soluble native-like Env trimer formulated with different adjuvants, 2) evaluation of lymph node germinal cell activities and B cell function and phenotype that have the potential to initiate development of HIV-1 broad neutralizing antibodies, and 3) advance high-throughput systems to interrogate the HIV-specific T cell repertoire following vaccination and identify profiles that may associate with immune protection in partially efficacious vaccine trials. Embedded in these studies will be selected analyses of response signatures in unique tissue sources and in diverse populations. These investigations will accelerate progress toward an effective vaccine by probing innate and adaptive immune responses at an unprecedented level in humans.

HIPC 3项目2的总体目标是鉴定HIV-1诱导的人类分子特征 与HIV-1保护潜在相关的疫苗和佐剂制剂 不同人群的感染。我们建议的调查将集中在三个领域， 关键的见解是需要：1）全面评估和比较的质量和 用可溶性免疫球蛋白免疫后增强的免疫应答效力和持久性 用不同佐剂配制的天然样Env三聚体，2）评估淋巴结增殖 细胞活性和B细胞功能和表型，有可能启动发展， HIV-1广泛中和抗体，和3）先进的高通量系统，以询问 疫苗接种后HIV特异性T细胞库，并确定可能与 部分有效疫苗试验中的免疫保护。在这些研究中， 对独特组织来源和不同人群中的反应特征进行选择性分析。 这些研究将通过探索先天性和先天性免疫， 人类的适应性免疫反应达到了前所未有的水平。